Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.
Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 and R21), expires: 01/14/2022
R01 Application Due Date(s): January 14, 2020, January 14, 2021, and January 14, 2022 by 5:00 PM local time of applicant organization.
R21 Application Due Date(s): January 14, 2020; January 14, 2021, by 5:00 PM local time of applicant organization
This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.